Mesa Laboratories, Inc. (NASDAQ:MLAB) has been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.

Brokerages have set a 12-month consensus price target of $190.00 for the company and are anticipating that the company will post $0.55 EPS for the current quarter, according to Zacks. Zacks has also given Mesa Laboratories an industry rank of 89 out of 265 based on the ratings given to its competitors.

Several research firms have recently issued reports on MLAB. Zacks Investment Research raised Mesa Laboratories from a “strong sell” rating to a “buy” rating and set a $167.00 price target for the company in a research report on Tuesday. TheStreet downgraded Mesa Laboratories from a “b” rating to a “c+” rating in a report on Monday, July 31st. Finally, BidaskClub downgraded Mesa Laboratories from a “sell” rating to a “strong sell” rating in a report on Saturday, August 12th.

Mesa Laboratories (NASDAQ:MLAB) traded up 0.86% during mid-day trading on Friday, hitting $153.29. 7,200 shares of the stock traded hands. The firm has a market cap of $576.06 million, a P/E ratio of 55.10 and a beta of 0.49. The firm’s 50-day moving average is $141.03 and its 200 day moving average is $140.68. Mesa Laboratories has a 52-week low of $109.14 and a 52-week high of $169.81.

Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings results on Monday, July 31st. The medical instruments supplier reported $0.39 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.17). The company had revenue of $22.67 million during the quarter, compared to analysts’ expectations of $22.90 million. Mesa Laboratories had a return on equity of 16.58% and a net margin of 11.31%. Equities analysts predict that Mesa Laboratories will post $2.74 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Thursday, November 30th will be issued a $0.16 dividend. The ex-dividend date of this dividend is Wednesday, November 29th. This represents a $0.64 annualized dividend and a yield of 0.42%. Mesa Laboratories’s payout ratio is 22.94%.

TRADEMARK VIOLATION NOTICE: “Analysts Expect Mesa Laboratories, Inc. (MLAB) to Announce $0.55 Earnings Per Share” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/analysts-expect-mesa-laboratories-inc-mlab-to-announce-0-55-earnings-per-share/1615583.html.

In related news, Director H Stuart Campbell sold 2,000 shares of Mesa Laboratories stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $143.37, for a total value of $286,740.00. Following the completion of the sale, the director now directly owns 49,976 shares in the company, valued at approximately $7,165,059.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 8,610 shares of company stock valued at $1,176,809 over the last quarter. 15.70% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Mesa Laboratories by 10.1% in the 2nd quarter. Vanguard Group Inc. now owns 145,161 shares of the medical instruments supplier’s stock worth $20,804,000 after buying an additional 13,263 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Mesa Laboratories by 3.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 129,320 shares of the medical instruments supplier’s stock worth $18,532,000 after buying an additional 4,634 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Mesa Laboratories by 9.8% in the 2nd quarter. Renaissance Technologies LLC now owns 87,271 shares of the medical instruments supplier’s stock worth $12,507,000 after buying an additional 7,771 shares in the last quarter. Royce & Associates LP increased its holdings in Mesa Laboratories by 56.8% in the 2nd quarter. Royce & Associates LP now owns 78,530 shares of the medical instruments supplier’s stock worth $11,254,000 after buying an additional 28,458 shares in the last quarter. Finally, Thomson Horstmann & Bryant Inc. increased its holdings in Mesa Laboratories by 75.4% in the 2nd quarter. Thomson Horstmann & Bryant Inc. now owns 72,362 shares of the medical instruments supplier’s stock worth $10,370,000 after buying an additional 31,107 shares in the last quarter. Institutional investors own 67.02% of the company’s stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Get a free copy of the Zacks research report on Mesa Laboratories (MLAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.